Eli Lilly and Company has begun US sales of Jentadueto, a drug for type 2 diabetes that combines Tradjenta and metformin. The drug, in tablet form, is taken twice daily and is available in three prescription strengths.
Tradjenta (linagliptin) is a DPP-4 inhibitor that regulates insulin levels. The drug was introduced less than a year ago to the US market.
Metformin, which regulates the liver’s glucose production, is an older standby drug that physicians often prescribe as the first drug therapy for recently diagnosed type 2s.
Lilly developed Tradjenta in conjunction with German drug maker Boehringer Ingelheim.